HSPA5 and neoplasm: In summary, pharmacological inhibition or knock‐down of HSPA5 reverted the enhanced malignancy of NRF3‐KO cells, demonstrating that the tumor‐suppressive function of NRF3 depends on its binding partner HSPA5 and the reduction in the levels of this pro‐tumorigenic UPR protein.